Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

ABSTRACT:

Aim

Warfarin pharmacogenomic algorithms reduce dosing error, but perform poorly in non-European-Americans. Electronic health record (EHR) systems linked to biobanks may allow for pharmacogenomic analysis, but they have not yet been used for this purpose.

Patients & methods

We used BioVU, the Vanderbilt EHR-linked DNA repository, to identify European-Americans (n = 1022) and African-Americans (n = 145) on stable warfarin therapy and evaluated the effect of 15 pharmacogenetic variants on stable warfarin dose.

Results

Associations between variants in VKORC1, CYP2C9 and CYP4F2 with weekly dose were observed in European-Americans as well as additional variants in CYP2C9 and CALU in African-Americans. Compared with traditional 5 mg/day dosing, implementing the US FDA recomm

SUBMITTER: Ramirez AH 

PROVIDER: S-EPMC3361510 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature